The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Triple-negative breast cancer, or TNBC, is a rare and especially aggressive form of breast cancer that grows and spreads ...

Publicly traded Peninsula drugmaker Gilead Sciences Inc. is trimming its Bay Area workforce after it announced it would do ...

Considering “health equity aspects”, Moupali Das highlighted the historic underrepresentation of disproportionately affected ...